Skip to main content
OpenTrials

Clinical trial condition

Ovarian Serous Adenocarcinoma

Explore clinical trials studying Ovarian Serous Adenocarcinoma. Study availability and eligibility vary by location and protocol.

26 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Ovarian Serous Adenocarcinoma trial results

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851

Conditions
Adenocarcinoma, Adenocarcinoma, Clear Cell, Adenocarcinoma, Mucinous, +51 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 709 locations
View Trial Details
Completed

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788

Conditions
Adenocarcinoma, Borderline Ovarian Serous Tumor, Carcinoma, +11 more
Locations
  • Tennessee Valley Gynecologic Oncology Huntsville, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 501 locations
View Trial Details
Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00951496

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +55 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
View all 503 locations
View Trial Details
Completed

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

NCT03648489

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • Charité Universitätsmedizin Berlin Berlin, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden Dresden, Germany
  • KEM Kliniken Essen-Mitte Essen, Germany
  • Furness General Hospital Barrow in Furness, Cumbria, United Kingdom
View all 15 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

NCT05074472

Conditions
Adenocarcinoma, Adnexal Diseases, Biliary Cancer Metastatic, +27 more
Locations
  • Mayo Clinic - Phoenix Phoenix, Arizona, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Mayo Clinic - Rochester Rochester, Minnesota, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View Trial Details
Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT01097746

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson Regional Care Center-Katy Houston, Texas, United States
  • MD Anderson Regional Care Center-Bay Area Nassau Bay, Texas, United States
  • MD Anderson Regional Care Center-Sugar Land Sugar Land, Texas, United States
View Trial Details
Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00888615

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +39 more
Locations
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California San Diego San Diego, California, United States
View all 163 locations
View Trial Details
Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00989651

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +59 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 23 locations
View Trial Details

Related conditions